Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

Inclusion Criteria: * Patients undergoing a cord blood or haploidentical transplantation on any protocol or standard of care treatment plan. * Age \>/= 18. * Females of child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding must be willing to use an effective contraceptive measure until 30 days after the last dose of eltrombopag. Males who have had sexual contact with female of child-bearing potential must be willing to use contraceptive techniques until 30 days after the last dose of eltrombopag. * Patient or patient's legal representative(s) is/are able to provide written informed consent to participate. Exclusion Criteria: * ALT and AST \>/= 2.5 ULN. * Serum direct bilirubin \>/= 1 mg/dl (except Gilbert's syndrome or hemolysis). * Patients of east Asian ancestry (Chinese, Japanese, or Korean Origin). * Calculated creatinine clearance \< 30ml./min. Creatinine clearance will be calculated using the MDRD method. * Arterial or venous thrombosis in the last year except for line-related venous thrombosis more than 3 months ago. * Positive beta HCG within 7 days prior to consent in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding.